{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sinusitis/prescribing-information/doxycycline/","result":{"pageContext":{"chapter":{"id":"e874a37b-5cc8-58c8-9335-ac01e3b17271","slug":"doxycycline","fullItemName":"Doxycycline","depth":2,"htmlHeader":"<!-- begin field 49041e8c-19a3-4ebe-b023-a8e800b414d1 --><h2>Doxycycline</h2><!-- end field 49041e8c-19a3-4ebe-b023-a8e800b414d1 -->","summary":"","htmlStringContent":"<!-- begin item 0908ed6b-02f3-4f3a-bd45-a8e800b413e1 --><!-- end item 0908ed6b-02f3-4f3a-bd45-a8e800b413e1 -->","topic":{"id":"6d2333af-675d-5bf3-8f7d-21404b5f0aa9","topicId":"251eec02-9620-4893-97bb-7a4e69e81da3","topicName":"Sinusitis","slug":"sinusitis","lastRevised":"Last revised in June 2018","chapters":[{"id":"2e4afda1-e9d5-5296-a027-01f4617ab6d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"405b3d6d-e395-5fea-bc5e-02ddf80a8bd2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"22d307e8-3756-562c-b49a-55d20a9d0c5d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"36290f8d-5730-5655-8fa4-0d3f584a2980","slug":"changes","fullItemName":"Changes"},{"id":"b0ba5cc8-0ed6-52d6-86c5-12833f47d8d3","slug":"update","fullItemName":"Update"}]},{"id":"f730377b-2158-527d-b9a1-e99c0653afd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5f96218a-0038-5b66-8c21-7db2d19f37b7","slug":"goals","fullItemName":"Goals"},{"id":"f4318fc5-fa1f-52cc-964f-2eeb9d4f7a27","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5a355772-1fc0-5033-929c-388a6956d7f5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"41d933ba-5f60-5f51-9a18-8d60f08747d9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"de2c52a0-2248-5977-a8e4-e495835a4f71","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"87fd2967-db43-5938-a83c-4761cd508da1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6b9273f7-5c2c-5994-a3d4-8617be04677e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"62fda2cc-020c-5dda-8886-be553f1b04bc","slug":"definition","fullItemName":"Definition"},{"id":"d0ca7ab5-8889-52dd-8ac6-bcf949adf403","slug":"causes","fullItemName":"Causes"},{"id":"6c331f3e-5cee-537d-9ff6-41dba5324ae1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2b91bcbf-5ce3-5cdb-bb8d-03f4297a60fc","slug":"complications","fullItemName":"Complications"}]},{"id":"17787dc5-901a-5bd4-93f1-b3bd7830f0a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a3d013cf-b195-59ed-ac16-d0dc956a2637","slug":"diagnosis-acute-sinusitis","fullItemName":"Diagnosis - acute sinusitis"},{"id":"35be5a2e-61f3-5478-b238-c91020678ab0","slug":"diagnosis-chronic-sinusitis","fullItemName":"Diagnosis - chronic sinusitis"},{"id":"3ec7ffd9-5556-5eb7-9e51-14b4e1403c11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a5e0292f-f277-5859-bf17-fe0b4557eae3","fullItemName":"Management","slug":"management","subChapters":[{"id":"851420e1-952f-58e9-bb2d-b69ed5134584","slug":"acute-sinusitis","fullItemName":"Scenario: Acute sinusitis"},{"id":"fe33ee40-93d8-59ba-b62a-2f9ccc74cc63","slug":"chronic-sinusitis","fullItemName":"Scenario: Chronic sinusitis"}]},{"id":"ccbcf182-fe04-59e6-abdc-75557dc3c700","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bc9974c3-e759-5746-8c96-b4538af16946","slug":"analgesia","fullItemName":"Analgesia"},{"id":"b7e24d48-87af-5f2c-9097-f4e3b1de894d","slug":"nasal-corticosteroids","fullItemName":"Nasal corticosteroids"},{"id":"5f63c8f8-0eaa-5fe0-b473-2d5e3aef00d1","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"0d802baf-8d25-5d8a-9c6d-b2a448983e4a","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"e874a37b-5cc8-58c8-9335-ac01e3b17271","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"bb4fef09-b30c-5637-ae85-ba203f26acd9","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"}]},{"id":"827f1e92-8727-5460-b9ae-00929701cc77","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dbc93c2-6562-533b-8dd9-0891fc35822e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8b0f7242-5fbb-5eb4-8b1a-13af5d4383df","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a3d9d72-ed21-52d6-ba45-abcfb27ec6b4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1b69a1e4-ec7f-5483-873c-2bb4bfb1345c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f04034ff-dd83-5bf5-83de-77fe9877df85","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f54f59b3-2893-5e4b-8dd2-3bee521cb237","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"164a0943-7f01-50bd-8c8f-a3695b72b662","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ccbcf182-fe04-59e6-abdc-75557dc3c700","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"77308711-e35e-59ad-b195-dc21c8f6eaad","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 17a42507-dd61-45a1-aa52-a8e800bb6569 --><h3>Cautions and contraindications</h3><!-- end field 17a42507-dd61-45a1-aa52-a8e800bb6569 -->","summary":"","htmlStringContent":"<!-- begin item 6c8d32cb-9af4-4b72-a1ba-a8e800bb6459 --><!-- begin field 357532d2-4ee8-4b4a-b43f-a8e800bb6569 --><ul><li><strong>Do not prescribe doxycycline in:</strong><ul><li>Women who are pregnant or breastfeeding, and children younger than 12 years of age.<ul><li>Tetracyclines are deposited in growing bone and teeth which can result in discolouration of teeth and occasionally dental hypoplasia.</li></ul></li></ul></li><li><strong>Prescribe doxycycline with caution in people with:</strong><ul><li>Hepatic impairment and those receiving potentially hepatotoxic drugs.</li><li>Myasthenia gravis — tetracyclines may increase muscle weakness in people with myasthenia gravis.</li><li>Systemic lupus erythematosus (SLE) — tetracyclines may exacerbate SLE symptoms.</li><li>Renal impairment — avoid excessive doses.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field 357532d2-4ee8-4b4a-b43f-a8e800bb6569 --><!-- end item 6c8d32cb-9af4-4b72-a1ba-a8e800bb6459 -->","subChapters":[]},{"id":"0a27aeb5-847e-5d43-8a0d-1f620baccac6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field bbf45aab-dfd6-40f1-b967-a8e800bb975e --><h3>Adverse effects</h3><!-- end field bbf45aab-dfd6-40f1-b967-a8e800bb975e -->","summary":"","htmlStringContent":"<!-- begin item abb1f941-25c5-4d1f-922e-a8e800bb9640 --><!-- begin field 5a346312-9db7-4ee3-b0bb-a8e800bb975e --><ul><li><strong>Blood disorders</strong> — haemolytic anaemia, thrombocytopenia, neutropenia, eosinophilia (rare).</li><li><strong>Gastrointestinal</strong> — nausea, vomiting (common), dyspepsia (uncommon).<ul><li><strong>Rarely:</strong> abdominal discomfort, diarrhoea, dysphagia, oesophagitis, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>. </li></ul></li><li><strong>Hepatic disorders</strong> — hepatotoxicity, hepatitis, jaundice, hepatic failure (rare).</li><li><strong>Renal disorders</strong> — blood urea increased.</li><li><strong>Skin</strong> — photosensitivity, rash (common).<ul><li><strong>Rarely:</strong> toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, drug reaction with eosinophilia and systemic symptoms (DRESS).</li></ul></li><li><strong>Other rare adverse effects include: </strong><ul><li>Anaphylaxis.</li><li>Arthralgia, myalgia.</li><li>Bulging fontanelles in infants.</li><li>Flushing.</li><li>Severe headache and/or visual disturbances — may be an early symptom of benign intracranial hypertension, a rare but serious adverse effect.</li><li>Tinnitus.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field 5a346312-9db7-4ee3-b0bb-a8e800bb975e --><!-- end item abb1f941-25c5-4d1f-922e-a8e800bb9640 -->","subChapters":[]},{"id":"53d1fe64-0fe1-528d-b48b-3b827fb4b761","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d56d68c2-dbd7-4b87-b7de-a8e800bbbbc0 --><h3>Drug interactions</h3><!-- end field d56d68c2-dbd7-4b87-b7de-a8e800bbbbc0 -->","summary":"","htmlStringContent":"<!-- begin item c11c789e-a0ce-4a7e-a971-a8e800bbbacd --><!-- begin field 0e35e982-23fb-4610-83f1-a8e800bbbbc0 --><ul><li><strong>Antacids (containing aluminium, bismuth, calcium, or magnesium) and other medications containing iron or zinc</strong> — these reduce the absorption of tetracyclines if taken concurrently.</li><li><strong>CYP3A enzyme inducers</strong> (for example, carbamazepine or phenytoin) — these may reduce the serum half-life of doxycycline. Monitor and adjust the dose if necessary.</li><li><strong>Methotrexate</strong> — levels may be increased by doxycycline.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of doxycycline.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Retinoids </strong>— there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids (such as isotretinoin).<ul><li>Avoid the concurrent use of tetracyclines and retinoids.</li></ul></li><li><strong>Rifampicin</strong> — doxycycline levels are markedly reduced, which may lead to treatment failure. Monitor the effects and increase doxycycline dose if necessary.</li><li><strong>Warfarin </strong>— the concurrent use of warfarin with tetracyclines may increase the anticoagulant effect. However, there is little evidence to suggest clinical relevance.<ul><li>Consider monitoring the person's international normalized ratio (INR) regularly and within 3 days of starting the tetracycline. Adjust the warfarin dose accordingly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field 0e35e982-23fb-4610-83f1-a8e800bbbbc0 --><!-- end item c11c789e-a0ce-4a7e-a971-a8e800bbbacd -->","subChapters":[]},{"id":"06dfef5b-8249-588e-b9a2-36f7460f2482","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 95a974a2-d4d8-4edc-8f6a-a8e800bbdbd3 --><h3>Pregnancy and breastfeeding</h3><!-- end field 95a974a2-d4d8-4edc-8f6a-a8e800bbdbd3 -->","summary":"","htmlStringContent":"<!-- begin item e4cd2393-fd61-4bff-9a05-a8e800bbd980 --><!-- begin field cff462fe-0ff9-47f2-abad-a8e800bbdbd3 --><h4>Pregnancy</h4><ul><li>Doxycycline is contraindicated in women who are pregnant because discolouration of the child's teeth may result from administration during the second or third trimester. Effects on skeletal development have been reported in animal studies. <ul><li>Doxycycline may be considered in the first trimester (for malaria prophylaxis) if required urgently and no suitable alternatives with a better safety profile are available.</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>Doxycycline is contraindicated in women who are breastfeeding.<ul><li>However, concerns about bone deposition of tetracyclines and possible staining of infant’s dental enamel have not been confirmed, and are unlikely during short-term use. Absorption by the infant is also inhibited by calcium in the breastmilk.</li><li>If other antibiotics are not appropriate, tetracycline is the preferred drug from this group. Short-term use (less than 3 weeks duration) is acceptable for most tetracyclines. Long-term use is not advisable.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">Fenner, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>] </p><!-- end field cff462fe-0ff9-47f2-abad-a8e800bbdbd3 --><!-- end item e4cd2393-fd61-4bff-9a05-a8e800bbd980 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}